ESC-Spezial: Was hypertrophen Herzen hilft!
Neuer Wirkstoff Mavacamten in HCM-Studie erfolgreich. Weitere Informationen: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Trial-supports-first-specific-treatment-for-obstructive-hypertrophic-cardiomyopathy https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31792-X/fulltext